Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.
A new compound product containing calcipotriol 50 nanograms per gm and betamethasone dipropionate 0.5mg per gm (Dovobet, LEO Pharma) in an ointment base was recently introduced in Canada for the treatment of psoriasis. Known as Daivobet in Europe, it was introduced to the Danish Market in 2001, and approved for marketing by the European Union. This compound has been shown to be more active than either agent used along. The efficacy of once daily application was not shown to be different from that of twice daily use.
Poulin
Y
Y
Department of Dermatology, Centre Hospitalier Universitaire de Quebec, Canada.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005938:Glucocorticoids; D006801:Humans; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D009824:Ointments; C055085:calcipotriene; D001623:Betamethasone; D002117:Calcitriol